Double activation and low IL-2 manufacturing protocol increase expansion of healthy and patient derived CAR-Tregs
Authors:
- Ugolini AlessiaUAUgolini Alessia
- Miceli AnnaMAMiceli Anna
- Bercher-Brayer ClaraBCBercher-Brayer Clara
- Cesarano SusannaCSCesarano Susanna
- Barbara CamisaBCBarbara Camisa
- Carulli PierluigiCPCarulli Pierluigi
- Monti PaoloMPMonti Paolo
- Ramirez Giuseppe AlviseRARamirez Giuseppe Alvise
- Bonomi ElisaBEBonomi Elisa
- Rudilosso LauraRLRudilosso Laura
- Dagna LorenzoDLDagna Lorenzo
- Cesana DanielaCDCesana Daniela
Open Access
- 9 July 2026
- journal article
- Published by Elsevier in Molecular Therapy Advances
- Vol. 34 (3)
Abstract
No abstract availableFunding Information
- Alleanza Contro il Cancro
- Ministero dell'Istruzione e del Merito
This publication has 41 references indexed in Scilit:
- Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committeeeClinicalMedicine, 2024
- Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progressionCellular Immunology, 2020
- Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptorCellular Immunology, 2020
- Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trialThe Lancet Rheumatology, 2019
- Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetesJournal of Autoimmunity, 2019
- A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical TrialsMolecular Therapy - Methods & Clinical Development, 2018
- CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial LandscapeMolecular Therapy, 2018
- Treg activation defect in type 1 diabetes: correction with TNFR2 agonismClinical & Translational Immunology, 2016
- Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacityExperimental Hematology, 2011
- Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulationEuropean Journal of Immunology, 2009